ArticlePediatric blood & cancer2026
Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431.
Article in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02567435 (A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRhabdomyosarcoma is the most common soft tissue sarcoma in pediatrics and infants are reported to have inferior outcomes. ARST1431 recommended delayed primary excision (DPE) while discouraging radiation (RT) deviations. This analysis compared outcomes among very young and older patients in this study. PROCEDURES: Demographic and tumor characteristics were summarized using frequencies and percentages. Local failure (LF) frequency was summarized by age group, RT, and DPE status. Event-free survival (EFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared between age groups using the log-rank test.
resultsOf 296 patients, 48 (16.2%) were <24 months: 14 (4.7%) < 12 months, 34 (11.5%) 12-24 months-compared with 248 (83.8%) ≥24 months. DPE was performed in: 7 (50%), <12 months; 9 (26%), 12-24 months; 56 (22%), ≥24 months. RT was given to 9 (64%), 27 (79%), and 195 (79%) of <12, 12-24, and >24 months, respectively. LF in DPE+RT was 8.3% and 6.1%, < 24 months and ≥ 24 months, respectively, compared to 29.3% and 20.5% for RT without DPE. The 4-year EFS did not vary: 56% (95% CI = 26.5, 86.0), 68% (95% CI = 51.2, 84.1), and 61% (95% CI = 54.2, 68.3) <12, 12-24, and >24 months old, respectively.
conclusionsOutcomes in younger children are comparable to older children with local failure more common in those without DPE. Optimization of local control will be important for future studies. TRIAL REGISTRATION NUMBER: NCT02567435.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.